| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0924-9338(01)00600-9 |
| P698 | PubMed publication ID | 11728855 |
| P2093 | author name string | Laughren TP | |
| P2860 | cites work | The continuing unethical use of placebo controls | Q28244803 |
| Consistency of atypical antipsychotic superiority to placebo in recent clinical trials | Q31864376 | ||
| Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database | Q33898438 | ||
| Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression | Q35180800 | ||
| Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary? | Q53555561 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| research ethics | Q1132684 | ||
| schizophrenia | Q41112 | ||
| P304 | page(s) | 418-423 | |
| P577 | publication date | 2001-11-01 | |
| P1433 | published in | European Psychiatry | Q5413047 |
| P1476 | title | The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective | |
| P478 | volume | 16 |
| Q36489406 | A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia |
| Q37014283 | A renewed, ethical defense of placebo-controlled trials of new treatments for major depression and anxiety disorders |
| Q24682133 | Antidepressants and suicide: risk-benefit conundrums |
| Q35102974 | Benefits and burdens of placebos in psychiatric research |
| Q28190011 | Clinical potential of omega-3 fatty acids in the treatment of schizophrenia |
| Q49924358 | Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. |
| Q34718444 | Did regulators fail over selective serotonin reuptake inhibitors? |
| Q37546125 | Drugs in development for the treatment of schizophrenia |
| Q57989648 | Ethical Issues in the Difference Between Placebo-Controlled and Active-Controlled Trials |
| Q42558211 | Ethical and Scientific Perspectives of Placebo-controlled Trials in Schizophrenia |
| Q37076279 | Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research |
| Q91938094 | Is High Placebo Response Really a Problem in Depression Trials? A Critical Re-analysis of Depression Studies |
| Q30533987 | Local IRBs vs. federal agencies: shifting dynamics, systems, and relationships |
| Q57171759 | Meta-analysis of Placebo Response in Randomized Clinical Trials of Antipsychotic Drugs Using PANSS Focusing on Different Approaches to the Handling of Missing Data |
| Q43758906 | Optimality, sample size, and power calculations for the sequential parallel comparison design |
| Q43235031 | Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study |
| Q42646762 | Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder |
| Q26776255 | Rethinking psychopharmacotherapy: The role of treatment context and brain plasticity in antidepressant and antipsychotic interventions |
| Q24241041 | Risperidone versus placebo for schizophrenia |
| Q24243436 | Risperidone versus placebo for schizophrenia |
| Q55894951 | Risperidone versus placebo for schizophrenia |
| Q31057535 | Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data from 12 years of clinical trials at the US National Institute of Mental Health |
| Q44606674 | Selective Serotonin Reuptake Inhibitors and Suicide: Is the Evidence, as with Beauty, in the Eye of the Beholder? |
| Q36582016 | Should desperate volunteers be included in randomised controlled trials? |
| Q26773320 | Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports |
| Q42931074 | The Use of Placebo-Controlled Clinical Trials for the Approval of Psychiatric Drugs: Part II-Ethical Considerations Related to the Individual Participant |
| Q38040453 | The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states? |
| Q33956817 | The investigator and the IRB: a survey of depression and schizophrenia researchers |
| Q35102476 | The new and evolving pharmacotherapy of schizophrenia |
| Q41909209 | The use of placebo-controlled clinical trials for the approval of psychiatric drugs: part I-statistics and the case for the "greater good". |
| Q41411828 | Time to abandon placebo control in pivotal phase III trials? |
| Q85097129 | Trial design issues and treatment effect modeling in multi‐regional schizophrenia trials |
Search more.